These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 4987716)

  • 1. Evaluation of group C meningococcal polysaccharide vaccine in marine recruits, San Diego, California.
    Devine LF; Pierce WE; Floyd TM; Rhode SL; Edwards EA; Siess EE; Peckinpaugh RO
    Am J Epidemiol; 1970 Jul; 92(1):25-32. PubMed ID: 4987716
    [No Abstract]   [Full Text] [Related]  

  • 2. Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state.
    Gotschlich EC; Goldschneider I; Artenstein MS
    J Exp Med; 1969 Jun; 129(6):1385-95. PubMed ID: 4977284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of meningococcal disease by group C polysaccharide vaccine.
    Artenstein MS; Gold R; Zimmerly JG; Wyle FA; Schneider H; Harkins C
    N Engl J Med; 1970 Feb; 282(8):417-20. PubMed ID: 4983754
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinico-immunological characteristics in children given meningococcal group A polysaccharide vaccine developed at the G. N. Gabrichevskĭ Moscow Research Institute of Epidemiology and Microbiology].
    Skirda TA; Golovina LI; Mishina AI; Chernyshova TF; Savchenko LG; Chernyshova MS
    Pediatriia; 1992; (2):55-9. PubMed ID: 1513635
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical and serological evaluation of a meningococcal polysaccharide vaccine groups A, C, Y, and W135.
    Hankins WA; Gwaltney JM; Hendley JO; Farquhar JD; Samuelson JS
    Proc Soc Exp Biol Med; 1982 Jan; 169(1):54-7. PubMed ID: 6801667
    [No Abstract]   [Full Text] [Related]  

  • 6. Development of polysaccharide vaccines for the prevention of meningococcal diseases.
    Gotschlich EC
    Monogr Allergy; 1975; 9():245-58. PubMed ID: 804088
    [No Abstract]   [Full Text] [Related]  

  • 7. The immunological responses observed in field studies in Africa with group A meningococcal vaccines.
    Gotschlich EC; Rey M; Etienne J; Sanborn WR; Triau R; Cvjetanović B
    Prog Immunobiol Stand; 1971; 5():485-91. PubMed ID: 4633975
    [No Abstract]   [Full Text] [Related]  

  • 8. [Serological evaluation of an antimeningococcal mass vaccination campaign in Niger].
    Rey JL; Soubiran G; Fayet MT; Triau R
    Bull Soc Pathol Exot Filiales; 1989; 82(2):248-54. PubMed ID: 2501041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
    Cohen R; Levy C
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meningococcal disease: a review on available vaccines and vaccines in development.
    Bröker M; Fantoni S
    Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meningococcal polysaccharide vaccines. Recommendation of the Public Health Service Advisory Committee on Immunization Practices.
    Conn Med; 1976 Jan; 40(1):57. PubMed ID: 812633
    [No Abstract]   [Full Text] [Related]  

  • 12. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.
    Zhang Q; Lakshman R; Burkinshaw R; Choo S; Everard J; Akhtar S; Finn A
    Infect Immun; 2001 Jul; 69(7):4337-41. PubMed ID: 11401971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunologic hyporesponsiveness in man to group C meningococcal polysaccharide.
    Artenstein MS; Brandt BL
    J Immunol; 1975 Jul; 115(1):5-7. PubMed ID: 807629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunoprophylaxis of meningococcal infection among the troops].
    Khokhlov DT; Efimov EI
    Voen Med Zh; 1984 Oct; (10):51-3. PubMed ID: 6438904
    [No Abstract]   [Full Text] [Related]  

  • 15. Present status of polysaccharide vaccines in the prevention of meningococcal disease.
    Gold R; Lepow ML
    Adv Pediatr; 1976; 23():71-93. PubMed ID: 12651
    [No Abstract]   [Full Text] [Related]  

  • 16. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease.
    Frasch CE; Borrow R; Donnelly J
    Vaccine; 2009 Jun; 27 Suppl 2():B112-6. PubMed ID: 19464093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tests of anti-meningococcal vaccination with A and C group polysaccharide vaccines].
    Galli MG; Fara GM; Saletti M; Porro M; Ribero ML
    Ann Sclavo; 1981; 23(3):356-66. PubMed ID: 6803687
    [No Abstract]   [Full Text] [Related]  

  • 18. Sulfa-drug resistance and serologic studies of a meningococcal meningitis epidemic.
    Sanborn WR
    J Egypt Public Health Assoc; 1969; 44(4):356-68. PubMed ID: 4985001
    [No Abstract]   [Full Text] [Related]  

  • 19. [Prophylaxis against menignococcal infections].
    Barr J
    Lakartidningen; 1969 Apr; 66(16):1674-82. PubMed ID: 4976974
    [No Abstract]   [Full Text] [Related]  

  • 20. [Immunity against Neisseria meningitidis in different population groups].
    Pauste Ruiz H; García Imia L; Campa Huergo C; Gutiérrez Hernández M; Valcárcel Novo M
    Rev Cubana Med Trop; 1989; 41(1):135-47. PubMed ID: 2505344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.